PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Dosing regimens

Protecting the dose, one of the most valuable forms of clinical IP.

Evolve is a specialist pharmaceutical and biotechnology IP firm. Our team includes scientific experts in chemistry, biochemistry and pharmaceutical science, and we have managed IP strategy for products at every stage of the pipeline, including on-market medicines.

Contact us

Our expertise FAQs Insights Contact us

Related technologies: New indications | Formulations | Life cycle management | T cell engagers

Dosing IP strategy

Unlike most formulations, the dose usually forms part of the label, so generics and biosimilars generally have to follow it. A well-supported dose patent can therefore provide protection long after the composition of matter patent expires.

Dose inventions are protected differently around the world. In the US they are claimed as methods of treatment, in Europe as second medical uses, and some offices, including China, give dosing features limited weight. We plan dose filings market by market. In Europe, a new dosage regime for a known medicine can be patented in the second medical use format. Dose patents are among the most valuable forms of clinical IP, which is why they are also among the most frequently challenged.

Showing an inventive dose

Patent offices often treat finding a safe and effective dose as routine. To succeed, the patent needs to show a surprising technical effect. In T 0792/24, a lower dose of plinabulin that was at least as effective as the higher dose was found inventive. Much of the real innovation in dose selection happens behind the scenes and never appears in regulatory submissions, so it has to be captured deliberately. Mechanistic insights can also support a dose invention.

Timing the filing

A study protocol is not the same as a dose invention. In one recent case, a priority document that described a dose-finding protocol without results could not support the later claim to the selected dose, and the priority claim failed. At the same time, the EPO may treat a published trial protocol as giving a reasonable expectation of success. Filing strategy has to balance both risks.

Mode of administration and dosing schedules

Step-up dosing, dosing intervals, premedication and the route of administration can all support claims. In T 0295/22, the Board of Appeal accepted that a mode of administration can be a new medical use, but the unexpected effects relied on were not enough for inventive step.

Later data cuts both ways

Post-published data can support inventive step, but it can also undermine a claim. Phase III results that cast doubt on the claimed effect have sunk a second medical use patent supported by phase II data.

Fractional IP counsel

Our fractional IP counsel model places a named senior patent attorney inside your team as your head of IP, working with your clinical team to capture dose innovation as it happens and to time filings around trials and regulatory submissions.

Why fractional IP counsel for dosing inventions? The innovation behind a dose is often hidden in clinical meetings and never reaches the regulatory file. A fractional head of IP from Evolve sits in those meetings, bringing the real-world industry experience that you only get working in-house to capturing dose inventions and timing filings around trials. Our team and AI tools, including the case law bank behind Popper, support them in a way no lone consultant can and few traditional IP firms do, with a global strategic approach.

Evolve AI

Popper, our prosecution agent, carries our case law bank on the evidence needed for clinical inventions, and Albert sets out the data behind competitor dose patents so that we can assess their strength quickly. Our attorneys still make every judgement call. Read more about Evolve AI.

Back to pharmaceuticals

FAQs

Can we patent a new dose of a known drug?

In the US and Europe, yes, as a method of treatment in the US and as a second medical use in Europe, if the dose is new and has a surprising technical effect over the prior art, supported by data. Read more: EPO pharma case law trends 2025: Clinical inventions

Do generics have to use our dose?

Usually, because the dose forms part of the label. That is why dose patents can be so valuable, and why they are so often challenged.

When should we file a dose patent?

When you have data showing the effect of the selected dose. Filing on a protocol alone risks losing priority, and waiting too long risks your own disclosures becoming prior art. Read more: A study protocol is not the same invention

Can later clinical data be used to support a dose patent?

It can support inventive step if the effect was already credible from the application as filed. It cannot fill a gap in the application, and it can also be used against you. Read more: Phase III results sink a second medical use patent

Dosing Evolve Insights

Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22)

  • 24th February 2026
At the EPO, it is perfectly possible for a therapeutic invention to survive without clinical data. The recent decision in T 1601/22 confirmed this sometimes surprisingly low bar for sufficiency in Europe for therapeutic inventions.
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image

EPO pharma case law trends 2025: Clinical inventions

  • 26th November 2025
The law in the pharma sector is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025, we review the most impactful decisions of the year relating to clinical-stage inventions. 
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Sufficiency at the priority date: A study protocol is not “the same” as a therapeutic effect invention (T 0883/23)

  • 31st October 2025
Therapeutic inventions are generally not considered sufficiently disclosed absent supporting data. The recent decision in T 0883/23 found that this applies both at the priority date and the filing date of the patent.
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image

Commercial success is a nothing-burger for the EPO in Wegovy patent inventive step analysis (T 1701/22, Obesity treatment with semaglutide)

  • 9th May 2025
Novo Nordisk’s recent setback with the European Patent Office (EPO) for semaglutide offers a critical lesson: even revolutionary drugs face patent rejection if their underlying composition, dose, and pH are deemed obvious in light of prior art, proving that commercial success alone cannot ensure patentability.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

A new mode of administration is a new specific medical use (but not necessarily inventive) (T 0295/22)

  • 8th February 2025
This post is based on a previous article on IPKat. The Board of Appeal decision in T 0295/22 tackles the question of whether a new mode of administration of a drug should be considered a new medical use. The Board of Appeal concludes that the current EPO Guidelines for Examination are wrong on this point, and that…
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Plausibility as a moving target: Phase III clinical trial results sink second medical use patent (T 0816/22)

  • 22nd January 2025
The Board of Appeal decision in T 0816/22 considered whether post-published phase III clinical trial data showing lack of efficacy can invalidate a second medical use patent that appeared plausible based on the data in the application as filed.
Three fused gold rings with a glowing turquoise centre ring on dark blue, Evolve abstract article image.
Three fused gold rings with a glowing turquoise centre ring on dark blue, Evolve abstract article image.

The criteria for the novelty and inventive step of pharmaceutical selection inventions (T 1356/21)

  • 31st January 2024
The recent Board of Appeal decision in T 1356/21 covered a number of interesting legal points in the field of pharmaceutical patents. The case related to the novelty and inventive step of a second medical use claim.
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Clinical trials: expectation of success, failure or mere hope?

  • 11th October 2022
Sitting in recent project meetings listening to the clinical team discuss possible signals from an oncology clinical trial, I was struck by the disconnect between the real life complexity and uncertainty versus the view taken by the EPO (and other patent offices) that the existence of a clinical trial protocol can give the skilled person…
View more Insights

Contact us

Tell us where your clinical programme is and what is coming up, whether that is a dose selection, a first filing, an opposition or a deal.

We are happy to have an informal conversation about your programme, with no obligation. You can read more about our team, and we also write a regular newsletter on pharma and biotech IP.

Contact us
Subscribe to the newsletter

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice